Author:
Golgooni Zeinab,Mirsadeghi Sara,Baghshah Mahdieh Soleymani,Ataee Pedram,Baharvand Hossein,Pahlavan Sara,Rabiee Hamid R.
Abstract
AbstractAimAn early characterization of drug-induced cardiotoxicity may be possible by combining comprehensive in vitro pro-arrhythmia assay and deep learning techniques. The goal of this study was to develop a deep learning method to automatically detect irregular beating rhythm as well as abnormal waveforms of field potentials in an in vitro cardiotoxicity assay using human pluripotent stem cell (hPSC) derived cardiomyocytes and multi-electrode array (MEA) system.Methods and ResultsWe included field potential waveforms from 380 experiments which obtained by application of some cardioactive drugs on healthy and/or patient-specific induced pluripotent stem cells derived cardiomyocytes (iPSC-CM). We employed convolutional and recurrent neural networks, in order to develop a new method for automatic classification of field potential recordings without using any hand-engineered features. In the proposed method, a preparation phase was initially applied to split 60-second long recordings into a series of 5-second long windows. Thereafter, the classification phase comprising of two main steps was designed. In the first step, 5-second long windows were classified using a designated convolutional neural network (CNN). In the second step, the results of 5-second long window assessments were used as the input sequence to a recurrent neural network (RNN). The output was then compared to electrophysiologist-level arrhythmia (irregularity or abnormal waveforms) detection, resulting in 0.84 accuracy, 0.84 sensitivity, 0.85 specificity, and 0.88 precision.ConclusionA novel deep learning approach based on a two-step CNN-RNN method can be used for automated analysis of “irregularity or abnormal waveforms” in an in vitro model of cardiotoxicity experiments.
Publisher
Cold Spring Harbor Laboratory
Reference38 articles.
1. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity
2. A Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening;Curr Protoc Pharmacol,2015
3. Vicente J , Zusterzeel R , Johannesen L , Mason J , Sager P , Patel V , Matta MK , Li Z , Liu J , Garnett C , Stockbridge N , Zineh I , Strauss DG . Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study. Clin Pharmacol Ther 2017.
4. Ligneau X , Shah RR , Berrebi-Bertrand I , Mirams GR , Robert P , Landais L , Maison-Blanche P , Faivre JF , Lecomte JM , Schwartz JC . Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies. Br J Pharmacol 2017.
5. Electrocardiographic biomarkers to confirm drug’s electrophysiological effects used for proarrhythmic risk prediction under CiPA;Journal of electrocardiology,2017